Accurate and reliable TOC measurements are vital in the modern water for injection (WFI) pharmaceutical production environment. But just having an online instrument installed in the ultra-pure water loop does not mean that your production quality is assured since many older models may give unreliable results. Here are five good reasons to think about upgrading to the latest ANATEL PAT700:
-
UV Detect: The UV lamp is the most critical component in a TOC analyzer. UV Detect technology exceeds the current industry practices of measuring hours in use or current flow through the lamp. Ensures that the UV output is always sufficient to completely oxidize the sample. Reduces the amount of system suitability testing needed so saving reagent costs and technician time.
-
Two UV Lamps: When the active lamp is no longer outputting the correct level of UV the PAT700 automatically switches to the other lamp to ensure a continuous flow of accurate readings. Maintenance can then be scheduled for a convenient time in the process cycle.
-
RFID Tagging on Standards Reagents: The standard’s data is automatically transferred to the instrument from the RFID tag so eliminating the incorrect use of standards and data entry errors.
-
Takes only Minutes to Run the Standards Tests: The standards tests take minutes instead of hours, can be scheduled to take place during non-manufacturing periods and, on successful completion, will automatically return the unit on-line without the operator being present.
-
Rapid Lamp Maintenance: The UV lamps can be changed in 15 minutes without the need for any special tools or gas.
The ANATEL PAT700 is designed to follow the FDA’s PAT guidance for on-line release of USP water. It has been designed from the ground up as a science and risk based instrument to ensure process compliance in the most demanding regulatory environments. A new 36 bottle autosampler is now available which can be used to increase bottle throughput when testing PW and WFI samples to meet the specific global pharmacopeia requirements for TOC and Conductivity.
Contact HACH LANGE for further information or visit our website for full details of the ANATEL PAT700.
|
|
|
|
|
|
|
|
|
|
|
|
Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, announced a major expansion of its research collaboration with Pfizer Inc. designed to discover new drugs to treat people with the most common mutation of CF, Delta F508.
Read the full story >>
|
|
 |
|
|
|
|
|
 |
|
FDA approves new indication for PROMACTA® (eltrombopag)
GlaxoSmithKline plc announced that the U.S.FDA has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy...
|
|
|
|
|
|
Featured news
 |
|
FOSS releases new version of Vision
FOSS NIRSystems, Inc. has introduced Vision 3.60. Vision is a software package specifically designed for use with the FOSS NIRSystems Near-Infrared (NIR) laboratory and process analyzers...
|
|
|
|
|
 Access the latest Biochemical Screening Technologies
Date: 4 – 6 December 2012
Venue: European ScreeningPort, Hamburg, Germany
European Pharmaceutical Review and European ScreeningPort are pleased to present a unique practical workshop covering the development of biochemical assays for screening purposes.
Taking place over three days at the European ScreeningPort facility in Hamburg, the workshop will offer attendees the chance to participate in practical sessions using the latest technology available from six of the top screening equipment / reagent vendors in the pharmaceutical industry.
Partnered by Thermo Fisher Scientific, PerkinElmer, GE Healthcare, BioTek, Promega and Cisbio Bioassays, this is a must-attend event for anyone in the drug discovery industry to learn about screening technologies and discover what they can do for your company or laboratory.
Find out more >>
|
|
** Recorded version now available to watch on-demand **
Rapid microbial testing methods in quality control continue to gain acceptance in pharmaceutical manufacturing, but most companies continue to use manual, traditional methods. The ability to uncover results in less time than traditional methods provides compelling benefits to manufacturers. These benefits can be realised in environmental monitoring, sterility testing, water and bioburden testing.
Learn from experts where rapid technologies, like the Growth Direct™ System can have an impact on microbial quality control and ultimately manufacturing.
Attendees of the event will learn:
* The limitations of the traditional methods
* The importance of non-destructive testing
* The benefits of automated, rapid detection
Watch here >>
|
|
Global Pharmaceuticals, Biotechnology and Life Sciences Industry Profile
The performance of the Global Pharmaceuticals, Biotechnology and Life Sciences market is forecast to accelerate by 6.8% for the five-year period 2011-2016, which is expected to drive the market to a value of $1,535.7 billion by the end of 2016. This Industry Profile is an essential resource for top-level data and analysis, providing insights into the Pharmaceuticals, Biotechnology and Life Sciences market across the globe.
Pharmaceuticals: Global Industry Almanac
The global pharmaceuticals market grew by 3.6% in 2010 to reach a value of $733,104.8 million. In 2015, the global pharmaceuticals market is forecast to have a value of $981,050.8 million, an increase of 33.8% since 2010.
The “Patent Cliff”: How Pfizer has responded to the loss of its best-selling drug
The global pharmaceuticals market was worth $733bn in 2010. With the patents of many of the world’s best-selling drugs expiring, the market is currently in the middle of a “patent cliff”. This Case Study looks at the various routes companies are taking in order to minimize the adverse effects caused by this “patent cliff”.
|
|
|
